Brief: Keros Therapeutics Strategic Committee Intends To Consider A Comprehensive Range Of Strategic Alternatives
08/05/2025 23:25
Keros Therapeutics Inc KROS.O: KEROS THERAPEUTICS: STRATEGIC COMMITTEE INTENDS TO CONSIDER A COMPREHENSIVE RANGE OF STRATEGIC ALTERNATIVES KEROS THERAPEUTICS: BOARD CONTINUES TO RECOMMEND STOCKHOLDERS VOTE "FOR" ITS 3 DIRECTOR NOMINEES Source text: ID:nGNX21BjKC Further company coverage: KROS.O
Recent news on Keros Therapeutics
See all newsBrief: Keros Therapeutics May Offer Up To $350 Million Of Securities - SEC Filing
Keros Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Keros Therapeutics Q2 net loss narrows on lower expenses
Brief: Keros Therapeutics - Keith Regnante Resigns As CFO
Keros Therapeutics posts Q1 net loss as license revenue drops